New hope for rare lung cancer mutations: targeted pill tested after surgery
NCT ID NCT05546866
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the targeted drug osimertinib can help prevent lung cancer from returning after surgery in patients with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take an 80 mg pill daily for up to 3 years. Researchers will track how many remain cancer-free at 2 and 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (a targeted cancer pill)
What this could lead to
If successful, this could provide an effective post-surgery treatment option for lung cancer patients with uncommon EGFR mutations, potentially delaying or preventing cancer return.
What could go wrong
This is a small, early-phase (Phase 2) study with only 51 participants and no comparison group. The results may not apply to all patients, and the drug has known side effects like rash and diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100730, China
-
Research Site
Chengdu, 610000, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Fuzhou, 350011, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Kunming, 650118, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shijiazhuang, 050051, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Tianjin, 300060, China